Madison, WI – Voximetry, a leader in advanced Radiopharmaceutical Therapy (RPT) dosimetry software and services, today announced that it will demonstrate Torch® Dose Assessment at the SNMMI 2026 Annual Meeting in the Siemens Healthineers booth (#1145).
Available to syngo.via users through the Siemens Healthineers Digital Marketplace, Torch gives clinicians access to Monte Carlo GPU-accelerated RPT dosimetry directly within their existing imaging workflow — without additional data handling steps or platform switching.
Attendees will have the opportunity to explore the Torch application within the Siemens Healthineers Digital Marketplace and experience how integrated dosimetry supports clinical decision-making and documentation of absorbed dose for the patient record.
“Dosimetry has become increasingly important as a first line of clinical defense,” said Dr. Sue Wallace, CEO of Voximetry. “Dosimetry provides a documented record of absorbed dose delivery that protects your patients and your practice in the future. The integration with syngo.via makes it quick and simple to save this information to the patient record.”
Torch Dose Assessment is recognized as the industry leader in accurate dosimetry, providing estimates of patient-specific pharmacokinetics and absorbed dose to tumors and critical structures.
The Siemens Healthineers Digital Marketplace provides syngo.via users with a curated ecosystem of advanced clinical applications, enabling direct access to innovative technologies like Torch Dose Assessment. Combined with syngo.via, Torch enables a simple, efficient data workflow while maintaining the highest level of scientific rigor – including superior management of density heterogeneity at the voxel level and unmatched Time Activity Curve fitting capabilities.
“Voximetry leads the science in RPT dosimetry and has a clear vision to stay ahead in the industry,” added Dr. Wallace. “Our partnership with Siemens Healthineers gives syngo.via users access to a trusted dosimetry solution — strengthening the clinical value of the platform at a pivotal moment for RPT.”
ABOUT VOXIMETRY
Voximetry is committed to delivering effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a software and services company pioneering advanced dosimetry to enable patient-specific radiopharmaceutical therapy (RPT) in cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and FDA-cleared. Torch design and development continue to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.
Torch design and development was also supported by grants from the University of Wisconsin-System SBIR Advance Matching Grant Fund through its partnership with the Wisconsin Economic Development Corporation.
For media inquiries, please contact marketing@voximetry.com.